Recent and new targets for small molecule anti-cancer agents

Drug Discovery Today: Technologies - Tập 6 - Trang e3-e11 - 2009
Huib Ovaa1, Coenraad Kuijl1, Jacques Neefjes1
1Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands

Tài liệu tham khảo

Goodman, 1984, JAMA, 251, 2255, 10.1001/jama.1984.03340410063036

Sneader, 2005

Farber, 1947, The action of pteroylglutamic conjugates on man, Science, 106, 619, 10.1126/science.106.2764.619

Farber, 1948, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid, N. Engl. J. Med., 238, 787, 10.1056/NEJM194806032382301

Dimarco, 1964, ‘Daunomycin’, a new antibiotic of the rhodomycin group, Nature, 201, 706, 10.1038/201706a0

Wall, 1966, Plant antitumor agents I. Isolation and structure of camtothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata, J. Am. Chem. Soc., 88, 3, 10.1021/ja00968a057

Pommier, 2009, DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition, Chem. Rev., 109, 2894, 10.1021/cr900097c

Wani, 1971, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J. Am. Chem. Soc., 93, 2325, 10.1021/ja00738a045

Goodman, 2001

Jordan, 2003, Tamoxifen: a most unlikely pioneering medicine, Nat Rev Drug Discov, 2, 205, 10.1038/nrd1031

Krum, 2008, Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival, EMBO J, 27, 535, 10.1038/sj.emboj.7601984

Zwart, 2007, Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha, Mol. Cancer Ther., 6, 1526, 10.1158/1535-7163.MCT-06-0750

Ghosh, 2009, Structural basis for androgen specificity and oestrogen synthesis in human aromatase, Nature, 457, 219, 10.1038/nature07614

Fleshner, 2007, Prostate cancer prevention: past, present, and future, Cancer, 110, 1889, 10.1002/cncr.23009

Hanks, 1995, Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification, FASEB J., 9, 576, 10.1096/fasebj.9.8.7768349

Kuijl, 2007, Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1, Nature, 450, 725, 10.1038/nature06345

Reuveni, 2002, Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design, Biochemistry, 41, 10304, 10.1021/bi0202530

Quintas-Cardama, 2007, Flying under the radar: the new wave of BCR–ABL inhibitors, Nat. Rev. Drug Discov., 6, 834, 10.1038/nrd2324

Tanaka, 2008, Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation, Expert Rev. Anticancer Ther., 8, 1387, 10.1586/14737140.8.9.1387

Heinrich, 2002, Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies, J. Clin. Oncol., 20, 1692, 10.1200/JCO.20.6.1692

Gray, 1998, Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN, Br. J. Cancer, 78, 1296, 10.1038/bjc.1998.674

Hannak, 2001, Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans, J. Cell Biol., 155, 1109, 10.1083/jcb.200108051

Giet, 2001, Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis, J. Cell Biol., 152, 669, 10.1083/jcb.152.4.669

Hardwicke, 2009, GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models, Mol. Cancer Ther., 8, 1808, 10.1158/1535-7163.MCT-09-0041

Senger, 1993, Vascular permeability factor (VPF, VEGF) in tumor biology, Cancer Metastasis Rev., 12, 303, 10.1007/BF00665960

Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938

Stephens, 2004, Lung cancer: intragenic ERBB2 kinase mutations in tumours, Nature, 431, 525, 10.1038/431525b

Kalikaki, 2008, Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC, Br. J. Cancer, 99, 923, 10.1038/sj.bjc.6604629

Zhang, 1998, Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties, Oncogene, 16, 2855, 10.1038/sj.onc.1201813

Richardson, 2003, A phase 2 study of bortezomib in relapsed, refractory myeloma, N. Engl. J. Med., 348, 2609, 10.1056/NEJMoa030288

Amir, 2002, The NEDD8 pathway is essential for SCF(beta-TrCP)-mediated ubiquitination and processing of the NF-kappa B precursor p105, J. Biol. Chem., 277, 23253, 10.1074/jbc.M200967200

Soucy, 2009, An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer, Nature, 458, 732, 10.1038/nature07884

Garg, 2002, Nuclear transcription factor-kappaB as a target for cancer drug development, Leukemia, 16, 1053, 10.1038/sj.leu.2402482

Zhou, 2009, Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047), J. Med. Chem., 52, 3028, 10.1021/jm801329v

Ray, 1994, The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis, Eur. Respir. J., 7, 2062, 10.1183/09031936.94.07112062

Fingleton, 2003, Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects, Expert Opin. Ther. Targets, 7, 385, 10.1517/14728222.7.3.385

Shih Ie, 2007, Notch signaling, gamma-secretase inhibitors, and cancer therapy, Cancer Res., 67, 1879, 10.1158/0008-5472.CAN-06-3958

Dunn, 2005, The Ras–MAPK signal transduction pathway, cancer and chromatin remodeling, Biochem. Cell Biol., 83, 1, 10.1139/o04-121

Njoroge, 1998, (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent, J. Med. Chem., 41, 4890, 10.1021/jm980462b

Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N. Engl. J. Med., 361, 123, 10.1056/NEJMoa0900212

Huang, 2009, Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling, Nature, 461, 614, 10.1038/nature08356

Barker, 2000, The Yin-Yang of TCF/beta-catenin signaling, Adv. Cancer Res., 77, 1, 10.1016/S0065-230X(08)60783-6

Guastafierro, 2008, CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery, J. Biol. Chem., 283, 21873, 10.1074/jbc.M801170200

Dantuma, 2006, A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling, J. Cell Biol., 173, 19, 10.1083/jcb.200510071